简化抗逆转录病毒治疗:一个很好的选择，为我们的病人和我们的卫生保健系统的可持续性

Farmacia Hospitalaria (English Edition) Pub Date : 2011-11-01 DOI:10.1016/j.farmae.2011.01.001

L. González Rivas , E. Sánchez Gómez , R. Sánchez del Moral , S. Grutzmancher Saiz , E. Pujol de la Llave , C. Bocanegra Martín

{"title":"简化抗逆转录病毒治疗:一个很好的选择，为我们的病人和我们的卫生保健系统的可持续性","authors":"L. González Rivas , E. Sánchez Gómez , R. Sánchez del Moral , S. Grutzmancher Saiz , E. Pujol de la Llave , C. Bocanegra Martín","doi":"10.1016/j.farmae.2011.01.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy.</p></div><div><h3>Method</h3><p>Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy.</p></div><div><h3>Results</h3><p>We identified 17 patients. Interval adherence was >95% in 9 patients, 90%–95% in 2 patients, 90%–85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36, and 48, except in 2 patients. The CD4 count in most analytical tests remained at >350cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116–8700).</p></div><div><h3>Conclusions</h3><p>In selected patients, monotherapy can be a cost-effective treatment option.</p></div>","PeriodicalId":100521,"journal":{"name":"Farmacia Hospitalaria (English Edition)","volume":"35 6","pages":"Pages 317-321"},"PeriodicalIF":0.0000,"publicationDate":"2011-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.farmae.2011.01.001","citationCount":"4","resultStr":"{\"title\":\"Simplification of Antiretroviral Therapy: A Good Choice for Our Patients and the Sustainability of Our Health Care System\",\"authors\":\"L. González Rivas , E. Sánchez Gómez , R. Sánchez del Moral , S. Grutzmancher Saiz , E. Pujol de la Llave , C. Bocanegra Martín\",\"doi\":\"10.1016/j.farmae.2011.01.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy.</p></div><div><h3>Method</h3><p>Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy.</p></div><div><h3>Results</h3><p>We identified 17 patients. Interval adherence was >95% in 9 patients, 90%–95% in 2 patients, 90%–85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36, and 48, except in 2 patients. The CD4 count in most analytical tests remained at >350cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116–8700).</p></div><div><h3>Conclusions</h3><p>In selected patients, monotherapy can be a cost-effective treatment option.</p></div>\",\"PeriodicalId\":100521,\"journal\":{\"name\":\"Farmacia Hospitalaria (English Edition)\",\"volume\":\"35 6\",\"pages\":\"Pages 317-321\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2011-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.farmae.2011.01.001\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmacia Hospitalaria (English Edition)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2173508512000044\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmacia Hospitalaria (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2173508512000044","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

摘要

目的评价洛匹那韦/利托那韦单药治疗的疗效、安全性、依从性和成本节约。方法采用观察性、描述性和回顾性研究评价单药治疗。采用客观方法计算依从性。我们估计了分配非三联疗法的直接成本。结果17例患者。9例患者的间歇依从性为95%，2例患者为90% ~ 95%，2例患者为90% ~ 85%，4例患者小于85%。在第12、24、36和48周，除2例患者外，未检测到病毒载量。在大多数分析测试中，CD4细胞计数保持在350细胞/ml，只有1例患者的数字较低。平均节省4819欧元/病人/年(范围1116-8700)。结论在选定的患者中，单药治疗是一种经济有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Simplification of Antiretroviral Therapy: A Good Choice for Our Patients and the Sustainability of Our Health Care System

Objective

To describe the efficacy, safety, compliance and cost savings of lopinavir/ritonavir monotherapy.

Method

Observational, descriptive and retrospective study evaluating monotherapy. Adherence was calculated using an objective method. We estimated the direct costs of dispensing non-triple therapy.

Results

We identified 17 patients. Interval adherence was >95% in 9 patients, 90%–95% in 2 patients, 90%–85% in 2 patients, and less than 85% in 4 patients. Viral load was undetectable during weeks 12, 24, 36, and 48, except in 2 patients. The CD4 count in most analytical tests remained at >350 cells/ml, only 1 patient had a lower figure. The average savings was 4819 Euros/patient/year (range 1116–8700).

Conclusions

In selected patients, monotherapy can be a cost-effective treatment option.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Farmacia Hospitalaria (English Edition)

自引率

0.00%

发文量